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Wednesday, February 24, 2010 763aHayashi and coworkers (2008, Biochemistry, 47, 6039), nicely, isolated soluble
Tetraprotomer (T), Diprotomer (D) and Protomer (P) from C12E8-solubilized
Na/K-ATPase and showed that Na/K-ATPase activity of T was around 50% of
those of D, P and membrane bound enzyme. Each P, D and T bound ATP in the
presence of excess EDTA with similar high affinity as the membrane bound en-
zyme. The binding of ATP and ouabain to T was 50-70% of those of P and D
(Hayashi et al., unpublished data). Each retention time for T, D and P accom-
panyingMg2þ-Naþ-dependent ATP hydrolysis with or without Kþ and that in
the absence of ATP was little affected. We measured the amount of EATP and
EP accompanying Mg2þ-Naþ-dependent ATP hydrolysis during the gel filtra-
tion in the presence of 12 micro M of [32P]ATP, which concentration nearly
saturates EP formation in membrane bound enzyme but not EATP formation.
The amount of EATP and EP in T, respectively, was 0.4350.01 (n=3) and
0.04-0.15 mol/protomer. Those in D and P, which were almost the same as
each other, were 0.4350.04 (n=6) and 0.09-0.21 mol/protomer, respectively.
Data suggest some enzymological property may change in the presence of
C12E8 or/and by solubilization.
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We are using structural biology, molecular biology, physiology, gene delivery
and preclinical testing to develop an optimized gene-therapy approach for the
treatment of heart failure (HF). A key abnormality in HF is defective function
of sarcoplasmic reticulum (SR). Deficient Ca2þ uptake during relaxation, asso-
ciated with a decrease in activity of SR Ca2þ-ATPase (SERCA2a), has been
identified in failing hearts from both humans and animal models. SERCA ac-
tivity is regulated by phospholamban (PLB), a small membrane protein that
partially inhibits SERCA in the absence of b-adrenergic phosphorylation of
PLB. Our approach combining structure-function analysis of PLB and the di-
rect detection of PLB-SERCA interactions relies on (a) fluorescence to show
that SERCA inhibition can be relieved without dissociation of PLB, (b) mag-
netic resonance to define the structural dynamics of PLB’s functional interac-
tion with SERCA, and (c) establishing structure-based computational design
principles to produce PLB mutants (PLBM) binding tightly to SERCA but hav-
ing decreased inhibitory potency. We have obtained evidence that non-inhibi-
tory PLB mutants S16E or L31A are capable of competing with WT-PLB to
reverse SERCA inhibition. We are currently testing the physical and functional
interaction between SERCA and optimized PLBM. Based on positive in vitro
results, rAAV is used to test PLBM in rodent and porcine HF models for in
vivo efficacy.
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Our enjoyable collaboration with Dr. Jeffrey P. Froehlich focused on the role of
phospholamban (PLN) in HNO-induced enhancement of SR Ca2þ-ATPase
(SERCA2a) activity. We hypothesized that given HNO thiophilic nature it
modifies cysteine residues in PLN transmembrane domain, altering its interac-
tion with SERCA2a, thus enhancing pump activity. When HNO, donated by
Angeli’s salt (AS), was administered to control isolated myocytes, it enhanced
both sarcomere shortening and Ca2þ transient. However, when AS/HNO was
applied to PLN-/- ventriculocytes, HNO inotropy was reduced by y 50%
(the remaining likely stemming from enhanced myofilament sensitivity to
Ca2þ). PLN centrality to HNO cardiotropic action was confirmed incubating
SR vesicles from WT and PLN-/- mice with AS/HNO to measure ATP-depen-
dent Ca2þ uptake by stopped-flow mixing. In WT, HNO increased Ca2þ uptake
rate, but it failed to do so in PLN-/- vesicles. The role of cysteines in PLN
emerged from studies using ER microsomes from Sf21 insect cells expressing
SERCA2a5PLN (WT or Cys 36-41-46/Ala mutant) where we assessed
SERCA2a dephosphorylation, a measure of E2P hydrolysis, i.e. a rate-limitingstep of SERCA2a activity. AS/HNO augmented SERCA2a dephosphorylation
in ER microsomes co-expressing SERCA2a and WT PLN, but this stimulation
was absent in microsomes expressing SERCA2a and Cys 36-41-46/Ala mu-
tant PLN. Thus, Jeff’s elegant, creative and passionate approach helped us to
show that PLN is essential for HNO-induced faster Ca2þ uptake by SERCA2a,
suggesting that HNO action occurs, at least partly, via modifications of critical
cysteines in PLN transmembrane domain. In Jeff’s view, ‘‘forbidden’’ disulfide
bonds in PLN are involved, and one of his legacies for us is unearthing the cys-
teine pairs that are involved in HNO-induced formation of an intramolecular
bond that could distort the conformation of PLN, thus perturbing its interaction
with SERCA2a and relieving the inhibition.
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Activation of cardiac muscle sarcoplasmic reticulum Ca2þ-ATPase (SER-
CA2a) by 1-agonists involves cAMP- and PKA-dependent phosphorylation
of phospholamban (PLB). Activation increases both the apparent Ca2þ affinity
and the Vmax of SERCA2a, requiring a sustained input of free energy during
cycling. In collaborative work with Jeffrey Froehlich, MD, and others, we in-
vestigated this process by comparing the kinetic and spectroscopic properties of
SERCA2a expressed with and without PLB in High Five insect cell micro-
somes to those of SERCA1 and SERCA2a in native skeletal and cardiac muscle
SR. Our data suggests PLB modifies the state of oligomerization of SERCA2a,
which in the presence of unphosphorylated, inhibitory PLB is predominantly
monomeric. The absence of PLB allows SERCA2a molecules to reorient and
interact conformationally, resulting in catalytic behavior characteristic of
SERCA1 in skeletal SR, which has no PLB. We propose that intermolecular
conformational coupling of SERCA2a units increases the catalytic efficiency
of the Ca2þ pump (raises Vmax) and may contribute to activation of the cardiac
SR Ca2þ pump induced by 1-adrenergic agonists. We have recently applied
these insights to the mechanism of SERCA2a stimulation by nitroxyl, HNO,
which we propose uncouples PLB from SERCA2a by modification of one or
more PLB cysteine residues. Dr. Froehlich’s kinetics studies indicated the
HNO-treated SERCA2a þPLB sample has the same kinetic properties as SER-
CA2a in the absence of PLB. SERCA2a coexpressed with a null-cysteine PLB
construct showed no change in kinetic properties following treatment with
HNO. Our ongoing fluorescence and electron paramagnetic resonance spectro-
scopic experiments agree, showing that HNO-treated SERCAþPLB samples
have physical properties similar to SERCA2a without PLB. Our results support
the conclusion that HNO-treatment, at least in part, uncouples PLB from SER-
CA2a, leading to HNO-stimulated SERCA2a activation. Direct effects of HNO
on SERCA2a are also under investigation.
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The Na pump is an ab heterodimer responsible for maintaining fluid and elec-
trolyte homeostasis in mammalian cells. We engineered MDCK cell lines ex-
pressing a1flag-, b1flag-, or b2myc-subunits via a tetracycline (tet)-regulated
promoter and a cell line expressing both stable b1myc and tet-regulated
b1flag in order to examine regulatory mechanisms of Na pump subunit expres-
sion. Overexpression of b1flag increases total b-subunit levels by greater than
200% without changes in a-subunit abundance, however, endogenous b1-sub-
unit (b1E) abundance is decreased. b1E down-regulation does not occur during
b2 overexpression. The decrease in b-subunit expression is not accompanied by
any change in mRNA levels. In addition, the degradation rate of b-subunits is
not altered by b1flag overexpression. Cells stably expressing b1myc, when in-
duced to express b1flag-subunits show reduced b1myc- and b1E-subunit
abundance, indicating that these effects occur via the coding sequences of
the down-regulated polypeptides. Similarly, MDCK cells over-expressing
a1flag-subunits exhibit a reduction of endogenous a1 (a1E) protein with no
change in a mRNA levels or b-subunits. The reduction in a1E compensates
for a1flag-subunit expression, resulting in unchanged total a-subunit abun-
dance. Thus, regulation of a-subunit expression maintains its native level
whereas b-subunit is not as tightly regulated and its abundance can increase
substantially over native levels. These effects are also seen in HEK cells.
This is the first indication that cellular Na pump subunit abundance is modu-
lated by translational repression. We will discuss the mechanism of this novel,
potentially important mode of Na pump regulation.
